The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin has been reported to have a beneficial effect on reducing the new onset of diabetes as well as lowering plasma lipids. Because pravastatin is a water-soluble organic anion, it cannot easily penetrate the lipid bilayer of the cell membrane. As the precise mechanisms of the effect of pravastatin on glucose metabolism and diabetes have not been clarified, we examined the roles of the organic anion transporter family on pravastatin-treated islet and adipocyte functions. Rat oatp1/slco1a1, oatp2/slco1a4 and oatp3/slco1a5 were expressed in the pancreas, and rat oatp3/slco1a5 was also detected in rat insulinoma cell line INS-1e. Pravastatin was transported not only by oatp1/slco1a1 and oatp2/slco1a4, but also by rat oatp3/slco1a5. Pravastatin uptake into INS-1e cells was detected and this transport was inhibited by sulfobromophthalein and rifampicin, both of which are known to inhibit oatp family-mediated uptake. In addition, pravastatin enhanced the glucose-stimulated insulin secretion from INS-1e cells. When fat-loaded db/db mice were treated with pravastatin, glucose intolerance and insulin resistance were prevented. In addition, insulin secretion from isolated islets was enhanced by pravastatin. These data suggest that pravastatin has pleiotropic effects on islets through membrane transport under high fat/glucose conditions.
Introduction
Pravastatin is a water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that has significant effects lowering total and LDL cholesterol and triglyceride levels. 1) In addition to these lipid-lowering effects, the West of Scotland Coronary Prevention Study (WOSCOPS) demonstrated the effectiveness of pravastatin therapy in inhibiting the new onset of diabetes. 2) Because of its hydrophilic nature, pravastatin cannot easily penetrate the cell membrane. To exert its effects, pravastatin has to be transported into cells via some kind of membrane transporter. 3) Recently, we isolated rat organic anion transporting polypeptide 2 (oatp2/slco1a4) as a transporter responsible for pravastatin uptake. 4, 5) In addition, LST-1/OATP-C/SLCO1B1 was also isolated and was identified as the molecule responsible for transporting pravastatin in human liver. 6, 7) However, no attempt was made to examine the transport of pravastatin into the islets or the effect of pravastatin on insulin secretion.
Here, we report the distribution of the oatp family in the pancreas; also the effects of pravastatin on insulin secretion are examined in vitro and in vivo.
Materials and Methods
Ethics statement/animals and experimental design: All research involving animals was conducted according to the national guidelines (Regulations and Guidelines on Scientific Care and Use of Laboratory Animals in Japan) and was also approved by the Tohoku University Animal Care Committee. Six-week-old, male db/db mice (＋Lepr db /＋Lepr db ) were purchased from CLEA (Tokyo, Japan). Mice were fed a high-fat diet (15.3% fat, 424.5 cal/100 g; Quick fat, CLEA, Tokyo, Japan) and had free access to tap water. At 7 weeks of age, mice that showed diabetic symptoms were randomly assigned to 2 groups: the control group and the pravastatin group (n＝5-12 per group). In the pravastatin group, 200 mg/kg body weight/day pravastatin was administered by gavage.
8)
Materials: Pravastatin was provided by DaiichiSankyo (Tokyo, Japan). Rat insulinoma cell line 9) INS-1e was kindly provided by Dr. Hisamitsu Ishihara, Nihon University.
Immunohistochemistry: Antibodies against rat oatp1/slco1a1, oatp2/slco1a4 and oatp3/slco1a5 and mouse oatp3/slco1a5 were raised using peptides. Synthetic peptides used for immunization were as follows; EN-DGELKTKL for rat oatp1/slco1a1 (amino acids 661-670), CTEVLRSKVTED for rat oatp2/slco1a4 (amino acids 650-661), KITVKKSEC for rat oatp3/slco1a5 (amino acids 643-651) and ETEKRIATHGVRC for mouse oatp3/slco1a5 (amino acids 2-15). Immunohistochemical analysis was performed as previously reported.
10)
The specificity of the immunohistochemical staining was further tested by Western blot analysis (data not shown).
Reverse transcription (RT)-PCR: The primers used for amplifying specific genes were as follows: rat oatp1/slco1a1 (forward 5?-TGTTGACCTGTGACAAT-GCA-3?, reverse 5?-TGCTCGCTTTCCTTCTCTCC-3?),  rat oatp2/slco1a4 (forward 5?-GAGTACCTTCTGTCTT-TCCTTAGCTA-3?, reverse 5?-AACTAACGCAATCTGG-CTTAACCAAG-3?), rat oatp3/slco1a5 (forward 5?-CGC-TTGGGATTGGATTACATGC-3?, reverse 5?-ATGAGAC-AGTGGCCTTTGGAGA-3?), mouse oatp1/slco1a1 (forward 5?-TTAGCTGGCATTCCGGCACCTG-3?, reverse  5?-CTTTAAAGTTCAGTGTGTGCGTCA-3?),  mouse  oatp2/slco1a4 (forward 5?-AACTAGGAAGACCATTGG-CCCTTTG-3?, reverse 5?-ATCCGAGGCATATTGGAG-GTAACATG-3 RT-PCR amplification was performed according to the following schedule: 949 C for 3 min, 949 C for 45 s, 579 C for 1 min, and 729 C for 2 min for 35 cycles, followed by further incubation for 10 min at 729 C.
Effects of drugs on glucose-stimulated insulin secretion (GSIS): INS-1e cells were grown in RPMI1640 and GSIS was measured as reported.
11)
In brief, cells ¿80% confluency were incubated in the presence or absence of pravastatin for 48 h. Cells were then maintained for 1 h, washed twice and preincubated at 379 C for 1 h in a buffer containing (in mM): 135 NaCl, 3.6 KCl, 5 NaHCO3, 0.5 NaH2PO4, 0.5 MgCl2, 1.5 CaCl2, 10 HEPES, and 0.1% BSA, pH 7.4.
Cells were then incubated with the buffer containing glucose for 60 min. The insulin concentration was measured using a rat insulin ELISA kit (Mercodia, Uppsala, Sweden).
Functional characterization of rat oatp3/ slco1a5: Pravastatin uptake by oatp3/slco1a5 was determined as described. 4, 6) Briefly, cDNA for rat oatp3/slco1a5 was synthesized and injected into defolliculated Xenopus laevis oocytes. Injected oocytes were cultured for 2-3 days and the uptake (60 min) of [ 14 C]pravastatin (30 mM) was measured (n＝4-6). Waterinjected oocytes were used as a control (n＝4-6).
Cellular uptake of pravastatin: Pravastatin uptake in INS-1e cells was measured as reported. 
12)
Cholesterol measurement: INS-1e cells (10 6 cells/well) or mouse islets (¿60 islets/tube) were homogenized with 200 ml of chloroform with 1% Triton X-100 and the extract was centrifuged for 10 min at 15,000 rpm. The cholesterol content of the organic phase was measured using a Cholesterol/Cholesteryl Ester Quantitation Kit (Biovision Labs, Mountain View, CA). 
Glucose tolerance test and insulin tolerance test:
Oral glucose tolerance testing (OGTT) was performed after overnight fasting. Two grams of glucose per kg body weight was administered orally. For insulin tolerance testing (ITT), 8-h fasted mice were injected with human regular insulin (2 U/kg body weight) intraperitoneally.
Measurement of insulin secretion from isolated islets: Islets were isolated as previously reported. 13) Ten islets were preincubated in RPMI1640 medium containing 10% FCS under 5% CO2 for 2 h at 379 C. The insulin secretion was stimulated by incubating islets in a medium containing 20 mM glucose for 30 min.
14)
The insulin concentration was determined using a mouse insulin kit (Morinaga, Yokohama, Japan).
Statistical analysis: Data are presented as means± SEM. Differences between groups were calculated using the unpaired Student's t-test. We considered Pº0.05 as statistically significant.
Results
Localization of rat oatps in the pancreas: Rat oatp1/slco1a1 was detected in the b-cells by immunohistochemical analysis (Fig. 1A) . Rat oatp2/slco1a4 immunoreactivity was detected in a-cells (Fig. 1B) . In contrast, rat oatp3/slco1a5 immunoreactivity was detected widely in the islets as well as acinar cells (Fig. 1C) . These signals were abolished using antibodies preabsorbed with antigen peptides (Supplemental Fig. 1) . Insulin (Fig.  1D) and glucagon (Fig. 1E) immunoreactivities were also used to confirmed the cellular identification. To further confirm the expression at the mRNA level, RT-PCR was performed. Individual specific bands were detected in the pancreas for rat oatp1/slco1a1 (Fig. 1F) , oatp2/slco1a4 (Fig. 1G) and for oatp3/slco1a5 (Fig . Fig. 2 . Effects of pravastatin on INS-1e cells (A) Radiolabeled pravastatin uptake by INS-1e cells with or without pravastatin (Prava) (1000 mM), rifampicin (300 mM) or BSP (300 mM).
31) (B) GSIS in INS-1e cells. Insulin was measured at 3.3 mM glucose (3.3 G) and 11 mM (11 G). In addition, the effects of pravastatin (30 mM) or pravastatin (30 mM) and BSP (30 mM) (n＝3) on GSIS in INS-1e cells were also measured. (C) Effect of BSP on pravastatin-induced insulin secretion at 3. 1H). In contrast, only the band for oatp3/slco1a5 was detected in INS-1e cells (Fig. 1H) . The mRNA quality was confirmed by using GAPDH as a control. These data suggest that there is molecular divergence between tissue and the cell line.
Pharmacological characterization: So far, there are no reports on oatp3/slco1a5-mediated pravastatin transport, although pravastatin is a preferred substrate for the oatp family, 5, 7) so we examined the pravastatin uptake by oatp3/slco1a5. Using the oocyte expression system, radiolabeled pravastatin uptake was found to be four-fold that of water-injected control oocytes: 0.10± 0.007 vs. 0.47±0.001 pmol/oocytes/min at 30 mM pravastatin (Pº0.05).
In vitro effect of pravastatin on INS-1e cells: Based on the expression of rat oatp3/slco1a5 in INS-1e, we next examined the pravastatin uptake by rat insulinoma cell line INS-1e 9) ( Fig. 2A) . The carrier-mediated pravastatin transport was evaluated by subtracting the value of inhibition by cold excess drugs. This uptake of radiolabeled pravastatin in INS-1e cells was significantly inhibited to 58.8% by 1000 mM pravastatin (n＝3). This uptake was abolished with rifampicin and slightly inhibited with sulfobromophthalein (BSP), both of which are known as inhibitors of oatp-mediated transport. 12) We next examined the effect of pravastatin on GSIS. In the control experiment, 11 mM and 20 mM glucose elicited 2.4-and 2.8-fold increments in insulin release, respectively, when compared to the value for 3.3 mM glucose (Fig. 2B, 2C ). As shown in Figure 2B and 2C, pravastatin significantly enhanced insulin release at 11 mM and 20 mM glucose. In addition, because the cellular cholesterol level has been reported to modulate exocytosis in b-cells, 15, 16) we measured the cholesterol con- tent of INS-1e cells and found that the cholesterol level is not different between control and pravastatin-treated cells (Fig. 2D) . This inhibitory effect of pravastatin transport by BSP was not caused by changes in cell viability because pravastatin and BSP had no effect on cell viability under these conditions (Fig. S2A) , although rifampicin had a small toxic effect. Thus, the primary inhibitory effect of pravastatin by BSP may be achieved by uptake inhibition of oatp transporter.
Effect of pravastatin on high-fat loaded db/db mice: To confirm the beneficial effect of pravastatin on the metabolic state, we next examined the effects of pravastatin in diabetic db/db mice. The body weight was similar between pravastatin-treated and control groups (Fig. 3A) . It has been reported that pravastatin decreased triglyceride levels without changing plasma cholesterol levels. 17) Clinically, pravastatin administration also increased adiponectin levels 18) and reduced urinary protein excretion. 19) To confirm these effect of pravastatin in a diabetic model, we measured the relevant parameters.
Pravastatin administration in db/db mice significantly decreased triglyceride levels after 3 weeks without changing the plasma cholesterol level (Fig. 3B) . The serum adiponectin level in the pravastatin-treated group was also significantly increased (Fig. 3C) . In addition, the urinary protein level was markedly reduced in the pravastatin-treated group (Fig. 3D) without evident histological differences (data not shown), confirming the effects of pravastatin in diabetic db/db mice.
Effect of pravastatin on glucose metabolism: We next examined the effect of pravastatin on glucose metabolism in vivo. Pravastatin significantly suppressed the fasting plasma glucose level of high-fat-loaded db/db mice 5 weeks after administration (Fig. 4A) . In addition, after 3 weeks of treatment, the serum glucose level dur- (Fig. 4B) . ITT also showed that pravastatin improved insulin resistance (Fig. 4C) . We next examined insulin secretion from the islets of db/db mice. We performed Western blotting of isolated islets to confirm the protein level of the oatp family (Fig. S3) . The insulin secretion of db/db mice decreased during fat loading (Fig. 4D) . Because diabetic mice suffer from pancreatic b-cell dysfunction, a decrease in GSIS in isolated islets from db/db mice is conceivable. 20) However, 4 weeks after administration of pravastatin, the insulin levels compared with the controls increased both at 0 min and 60 min after glucose stimulation. Furthermore, the insulin level of the pravastatin-treated group 4 weeks after administration of prava was decreased compared to the level at 2 weeks after administration. These data suggest that the improvement of OGTT results by pravastatin is attributed to the protective effect on insulin secretion of high-fat/glucose-loaded b-cells, in addition to improving insulin tolerance.
We next demonstrated the potentiating effect on insulin secretion in vivo by pravastatin in the isolated islets from high-fat/glucose-fed db/db mice. When islets were stimulated by 20 mM glucose, insulin secretion in the pravastatin-treated db/db group was significantly increased (Fig. 5A) . Because it has been reported that the cholesterol level in the islet influences the b-cell function, 21) we measured the cholesterol level in the isolated islets. The cholesterol level of pravastatin-treated mice islets was reduced (Fig. 5B) . These data further suggest that lipid accumulation hampers insulin secretion under high glucose conditions. We also examined the existence of the oatp family in mouse pancreas. As shown in Figure 5C , mouse oatp2/slco1a4 (left panel) and oatp3/slco1a5 (right panel) mRNA were detected in the pancreas. Immunohistochemical analysis also detected mouse oatp3/slco1a5 immunoreactivity in the islets (Fig.  5D) . Because HMG-CoA reductase was detected in the islets and INS-1e cells (Fig. 5E) , these data suggest that pravastatin transported into the islets decreases the cholesterol content following the improvement of insulin secretion. We measured the concentration of cellular cholesterol in INS-1e cells under normal cell culture conditions (Fig. 2D) . On the other hand, in Figure 5B , we show results using islets collected from diabetic high-fatfed db/db mice. The difference in the fat conditions between these two experiments could be responsible for the differences seen in the cellular cholesterol level, suggesting the possibility that statins could be very effective under high-cholesterol condition.
Discussion
Statins have a wide variety of pleiotropic effects on endothelial function, smooth muscle proliferation, and vascular inflammation. 22) Pravastatin has a water-soluble nature and therefore it cannot easily penetrate the lipid bilayer without the aid of membrane transport system(s). Recent studies have elucidated the contribution of the oatp family to the membrane transport of pravastatin. Rat oatp1/slco1a1 accepts a broad range of amphipathic compounds, including bile acids, steroids, eicosanoids and peptidomimetics and is localized in the liver and kidney. 23) Rat oatp2/slco1a4 is abundantly expressed in the liver and the central nervous system. 4) Rat oatp2/slco1a4 also mediates uptake of bile acids and cardiac glycosides. Rat oatp3/slco1a5 is highly expressed in the kidney, brain and retina and mediates transport of bile acids and thyroid hormones. 4) Concerning pravastatin, recent studies elucidated that both oatp1/slco1a1 24) and oatp2/slco1a4 5) contribute to its membrane transport, and here, we report the evidence for oatp3/slco1a5-mediated pravastatin transport.
In histochemical analysis, immunoabsorption with antibodies with antigen peptides reinforced the specificity of the immunoreactivity and the clear expression of the oatp family in the islets (Supplementary Fig. 1) . Thus, the existence of the oatp family and its uptake properties suggests that the membrane transport of pravastatin occurs in pancreas and islets (Figs. 1, 5) .
In Figure 2A , 300 mM BSP slightly inhibited carriermediated pravastatin uptake into INS-1e cells. On the other hand, 30 mM of BSP completely abolished the increase in insulin secretion by pravastatin (Fig. 2B) . In the uptake study, INS-1e cells were incubated with BSP with radiolabeled-pravastatin for only 5 min. On the other hand, in GSIS, INS-1e cells were treated with pravastatin for 48 h. The differences in experimental procedures or long-term exposure to inhibitor(s) may possibly yield further metabolic cellular inhibition even at low concentrations. A similar phenomenon in terms of the concentration difference between statin uptake inhibition (¿mM order) 25) and the inhibition of cholesterol biosynthesis cascade (¿nM order) has been reported. 26) Further experiments are needed to clarify these differences in different assay systems.
Pravastatin reduced glucose levels during OGTT in db/db mice fed with a high-fat diet (Fig. 4B) . Type 2 diabetes is marked by a relative inability of the pancreas to secrete sufficient insulin to meet metabolic demands. Although the pathogenesis of b-cell dysfunction remains obscure, one proposed mechanism is lipotoxicity, in which toxic lipid accumulation leads to b-cell apoptosis and the loss of insulin secretion. 16, 21) Recently, Brunham et al. reported that lipid accumulation as a result of bcell-specific disruption of cholesterol transporter ABCA1 reduced insulin secretion and influenced glucose homeostasis 21) and also that lowering the b-cell cholesterol level increases insulin secretion. 27) Because the accumulation of cholesterol in b-cells inhibits insulin secretion in the pathway before membrane depolarization, high KCl levels stimulate calcium-dependent increases in both insulin secretion and phospholipase C activation. 21) In our study, high KCl levels also increase insulin secretion (data not shown). The expression of mouse oatp2/slco1a4 and oatp3/slco1a5 in the islets and the reduction of cholesterol content in isolated islets from high-fat-loaded db/db mice treated with pravastatin suggested that the transport of pravastatin and modulation of the cholesterol level in the islets may be responsible for the augmented insulin secretion and reduction of serum glucose levels. In our experiment, the stimulatory effect of pravastatin on insulin secretion occurred when the glucose concentration was high (Fig. 5A) . Differences in environmental glucose conditions might have caused differences in the cholesterol level between INS1e cells and isolated islets. In addition, there was no significant difference in the size of islet area between pravastatin-treated and non-treated mice (Supplementary Fig. 2B ). These data further suggest the pleiotropic effect of pravastatin.
In contrast to our findings, Ishikawa et al. reported that pravastatin, atorvastatin and simvastatin had no effect on GSIS in the mouse b-cell line MIN6. 28) They also showed that GSIS of islet cells isolated from C57BL/6 mice was not significantly affected by statins irrespective of their class. 28) The differences might be attributable to the experimental design such as drug application, duration, and cell line. It has not been clarified that MIN6 has the necessary machinery to take up pravastatin into cells.
Our data also revealed that not only did pravastatin stimulate insulin secretion, but that it also improved insulin sensitivity (Fig. 4C) . Recently, several groups have reported that pravastatin improved insulin resistance. 2, 29) Especially, Takagi et al. reported that pravastatin attenuated the development of insulin resistance in obese diabetic models by upregulating glucose uptake in white adipose tissue. 30) On the face of it, these two findings may beneficially and synergistically converge in improving diabetic status under diabetic conditions.
In conclusion, these findings suggest that the uptake of pravastatin into b-cells via oatp transporter(s) contributes to insulin secretion. Further studies on human transporter would be helpful to understand these effects in patients suffering from diabetes and obesity.
